Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Forensic Sci Int ; 261: 137-47, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26930544

RESUMO

In 2010-2013, 29 fatal intoxications related to the designer drug paramethoxymethamphetamine (PMMA, 4-methoxymethamphetamine) occurred in Norway. The current knowledge about metabolism and toxicity of PMMA in humans is limited. Metabolism by the polymorphic cytochrome P450 (CYP) 2D6 enzyme to the psychoactive metabolite 4-hydroxymethamphetamine (OH-MA), and possibly by additional enzymes, is suggested to be involved in its toxicity. The aim of this work was to study the association between CYP genetics, PMMA metabolism and risk of fatal PMMA toxicity in humans. The frequency distribution of clinically relevant gene variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A5, and the phenotypic blood CYP2D6 metabolic ratio (OH-MA/PMMA) in particular, were compared in fatal PMMA intoxications (n=17) and nonfatal PMMA abuse controls (n=30), using non-abusers (n=305) as references for the expected genotype frequencies in the Norwegian population. Our study demonstrated that the CYP2D6 enzyme and genotype are important in the metabolism of PMMA to OH-MA in humans, but that other enzymes are also involved in this biotransformation. In the fatal PMMA intoxications, the blood concentrations of PMMA were higher and the CYP2D6 metabolic ratios were lower, than in the nonfatal PMMA abuse controls (median (range) 2.1 (0.03-5.0) vs 0.3 (0.1-0.9) mg/L, and ratio 0.6 (0.0-4.6) vs 2.1 (0.2-7.4) p=0.021, respectively). Overall, our findings indicated that, in most cases, PMMA death occurred rapidly and at an early stage of PMMA metabolism, following the ingestion of large and toxic PMMA doses. We could not identify any genetic CYP2D6, CYP2C9, CYP2C19 or CYP3A5 predictive marker on fatal toxicity of PMMA in humans. The overrepresentation of the CYP2D6 poor metabolizer (PM) genotype found in the nonfatal PMMA abuse controls warrants further investigations.


Assuntos
Sistema Enzimático do Citocromo P-450/genética , Drogas Desenhadas/farmacocinética , Genótipo , Metanfetamina/análogos & derivados , Adulto , Estudos de Casos e Controles , Drogas Desenhadas/análise , Drogas Desenhadas/intoxicação , Feminino , Toxicologia Forense , Humanos , Masculino , Metanfetamina/sangue , Metanfetamina/farmacocinética , Metanfetamina/intoxicação , Pessoa de Meia-Idade , Farmacogenética , Reação em Cadeia da Polimerase em Tempo Real , Adulto Jovem
2.
Basic Clin Pharmacol Toxicol ; 115(6): 565-70, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24891132

RESUMO

A variety of techniques have been developed to monitor the depth of anaesthesia. Propofol's pharmacokinetics and response vary greatly, which might be explained by genetic polymorphisms. We investigated the impact of genetic variations on dosage, anaesthetic depth and recovery after total intravenous anaesthesia with propofol. A total of 101 patients were enrolled in the study. The plasma concentration of propofol during anaesthesia was measured using high-performance liquid chromatography. EEG was monitored during the surgical procedure as a measure of anaesthetic depth. Pyrosequencing was used to determine genetic polymorphisms in CYP2B6, CYP2C9, the UGTIA9-promotor and the GABRE gene. The correlation between genotype and to plasma concentration at the time of loss of consciousness (LOC), the total induction dose, the time to anaesthesia, eye opening and clearance were investigated. EEG monitoring showed that the majority of the patients had not reached a sufficient level of anaesthetic depth (subdelta) at the time of loss of consciousness despite a high induction dose of propofol. Patients with UGT1A9-331C/T had a higher propofol clearance than those without (p = 0.03) and required a higher induction dose (p = 0.03). The patients with UGT1A9-1818T/C required a longer time to LOC (p = 0.03). The patients with CYP2C9*2 had a higher concentration of propofol at the time of LOC (p = 0.02). The polymorphisms in the metabolizing enzymes and the receptor could not explain the large variation seen in the pharmacokinetics of propofol and the clinical response seen. At LOC, the patients showed a large difference in EEG pattern.


Assuntos
Anestésicos Intravenosos/farmacologia , Eletroencefalografia/efeitos dos fármacos , Propofol/farmacologia , Adulto , Anestésicos Intravenosos/sangue , Anestésicos Intravenosos/farmacocinética , Citocromo P-450 CYP2B6/genética , Citocromo P-450 CYP2C9/genética , Feminino , Genótipo , Glucuronosiltransferase/genética , Humanos , Masculino , Polimorfismo Genético , Propofol/sangue , Propofol/farmacocinética , Receptores de GABA-A/genética , UDP-Glucuronosiltransferase 1A
3.
Forensic Sci Int ; 238: 125-32, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24709712

RESUMO

The major purpose of this study was to elucidate if genotyping can facilitate interpretations of tramadol (TRA) in forensic case work, with special regard to the estimation of the time of drug intake and drug related symptoms (DRS). The association between genetic polymorphisms in CYP2D6, OPRM1 and ABCB1 and pharmacokinetic and pharmacodynamic properties of TRA was studied. Nineteen healthy volunteers were randomized into two groups receiving a single dose of either 50 or 100mg of orally administrated TRA. Blood samples were collected prior to dosing and up to 72h after drug intake. The subjects were asked to report DRS during the experimental day. We found a positive correlation between the metabolic ratio of O-desmethyltramadol (ODT) to TRA and the time after drug intake for both CYP2D6 intermediate metabolizers and extensive metabolizers. For the only poor metabolizer with detectable ODT levels the metabolic ratio was almost constant. Significant associations were found between the area under the concentration-time curve (AUC) and three of the investigated ABCB1 single nucleotide polymorphisms for TRA, but not for ODT and only in the 50mg dosage group. There was great interindividual variation in DRS, some subjects exhibited no symptoms at all whereas one subject both fainted and vomited after a single therapeutic dose. However, no associations could be found between DRS and investigated polymorphisms. We conclude that the metabolic ratio of ODT/TRA may be used for estimation of the time of drug intake, but only when the CYP2D6 genotype is known and taken into consideration. The influence of genetic polymorphisms in ABCB1 and OPRM1 requires further study.


Assuntos
Analgésicos Opioides/farmacocinética , Citocromo P-450 CYP2D6/genética , Polimorfismo de Nucleotídeo Único , Receptores Opioides mu/genética , Tramadol/farmacocinética , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Administração Oral , Adulto , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/sangue , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Feminino , Genética Forense , Toxicologia Forense , Genótipo , Humanos , Masculino , Espectrometria de Massas , Farmacogenética , Distribuição Aleatória , Tramadol/administração & dosagem , Tramadol/análogos & derivados , Tramadol/sangue
4.
Basic Clin Pharmacol Toxicol ; 115(5): 423-31, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24703092

RESUMO

Therapeutic modulation of pain with morphine and other opioids is associated with significant variation in both effects and adverse effects in individual patients. Many factors including gene polymorphisms have been shown to contribute to the interindividual variability in the response to opioids. The aim of this study was to investigate the significance of UGT2B7, OPRM1 and ABCB1 polymorphisms for interindividual variability in morphine-induced analgesia in patients undergoing hysterectomy. The frequency of these polymorphisms was also investigated in forensic autopsies as morphine is also a very commonly abused drug. Blood samples were collected from 40 patients following abdominal hysterectomy, 24 hr after initiation of analgesia through a patient-controlled analgesia (PCA) pump. Samples were genotyped and analysed for morphine and its metabolites. We also genotyped approximately 200 autopsies found positive for morphine in routine forensic analysis. Patients homozygous for UGT2B7 802C needed significantly lower dose of morphine for pain relief. The same trend was observed for patients homozygous for ABCB1 1236T and 3435T, as well as to OPRM1 118A. The dose of morphine in patients included in this study was significantly related to variation in UGT2B7 T802C. Age was significantly related to both dose and concentration of morphine in blood. Regression analysis showed that 30% of differences in variation in morphine dose could be explained by SNPs in these genes. The genotype distribution was similar between the forensic cases and the patients. However, the mean concentration of morphine was higher in forensic cases compared to patients. We conclude that gene polymorphisms contribute significantly to the variation in morphine concentrations observed in individual patients.


Assuntos
Glucuronosiltransferase/genética , Morfina/administração & dosagem , Receptores Opioides mu/genética , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Adulto , Fatores Etários , Idoso , Analgesia Controlada pelo Paciente/métodos , Analgésicos Opioides/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Genótipo , Humanos , Histerectomia/métodos , Pessoa de Meia-Idade , Dor Pós-Operatória/tratamento farmacológico , Polimorfismo de Nucleotídeo Único , Análise de Regressão
5.
Pharmacogenet Genomics ; 23(9): 463-9, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23820292

RESUMO

BACKGROUND: Polymorphisms in ABCB1 have the ability to affect both the function and the expression of the transporter protein P-glycoprotein and may lead to an altered response for many drugs including some antidepressants and antipsychotics. OBJECTIVE: The aim of this study was to examine the impact of the ABCB1 polymorphisms 1199G>A, 1236C>T, 2677G>T/A, and 3435C>T in deaths by suicide. PATIENTS AND METHODS: A total of 998 consecutive Swedish forensic autopsies performed in 2008 in individuals 18 years of age or older, where femoral blood was available and a toxicological screening had been performed, were investigated. Genotypes were assessed with pyrosequencing and information on the cause and manner of each death was obtained from the forensic pathology and toxicology databases. RESULTS: There was a significantly higher frequency of the T allele at positions 1236, 2677, and 3435 among the suicide cases compared with the nonsuicide cases. CONCLUSION: Our result from forensic cases suggests that ABCB1 polymorphisms are associated with an increased risk for completed suicides. The biological mechanisms involved and the clinical implications for these findings are largely unknown and need to be examined further.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Polimorfismo de Nucleotídeo Único , Suicídio , Subfamília B de Transportador de Cassetes de Ligação de ATP , Adulto , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/sangue , Antipsicóticos/sangue , Autopsia , Feminino , Patologia Legal/legislação & jurisprudência , Variação Genética , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
6.
Forensic Sci Int ; 214(1-3): 124-34, 2012 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-21840145

RESUMO

Venlafaxine (VEN) is an antidepressant drug mainly metabolized by the cytochrome P450 (CYP) enzyme CYP2D6 to the active metabolite O-desmethylvenlafaxine (ODV). VEN is also metabolized to N-desmetylvenlafaxine (NDV) via CYP3A4. ODV and NDV are further metabolized to N,O-didesmethylvenlafaxine (DDV). VEN is a racemic mixture of the S- and R-enantiomers and these have in vitro displayed different degrees of serotonin and noradrenaline reuptake inhibition. The aim of the study was to investigate if an enantioselective analysis of VEN and its metabolites, in combination with genotyping for CYP2D6, could assist in the interpretation of forensic toxicological results in cases with different causes of deaths. Concentrations of the enantiomers of VEN and metabolites were determined in femoral blood obtained from 56 autopsy cases with different causes of death. The drug analysis was done by liquid chromatography tandem mass spectrometry (LC/MS/MS) and the CYP2D6 genotyping by PCR and pyrosequencing. The mean (median) enantiomeric S/R ratios of VEN, ODV, NDV and DDV were 0.99 (0.91), 2.17 (0.93), 0.92 (0.86) and 1.08 (1.03), respectively. However, a substantial variation in the relationship between the S- and R-enantiomers of VEN and metabolites was evident (S/R ratios ranging from 0.23 to 17.6). In six cases, a low S/R VEN ratio (mean 0.5) was associated with a high S/R ODV ratio (mean 11.9). Genotyping showed that these individuals carried two inactive CYP2D6 genes indicating a poor metabolizer phenotype. From these data we conclude that enantioselective analysis of VEN and ODV can predict if a person is a poor metabolizer genotype/phenotype for CYP2D6. Knowledge of the relationship between the S- and R-enantiomers of this antidepressant drug and its active metabolite is also important since the enantiomers display different pharmacodynamic profiles.


Assuntos
Antidepressivos de Segunda Geração/sangue , Cicloexanóis/sangue , Citocromo P-450 CYP2D6/genética , Genótipo , Cromatografia Líquida , Succinato de Desvenlafaxina , Toxicologia Forense , Humanos , Estereoisomerismo , Espectrometria de Massas em Tandem , Cloridrato de Venlafaxina
8.
Clin Chem ; 51(3): 522-31, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15650034

RESUMO

BACKGROUND: Identification of CYP2D6 alleles *5 (deletion of the whole CYP2D6 gene) and *2xN (gene duplication) is very important because they are associated with decreased or increased metabolism of many drugs. The most commonly used method for analysis of these alleles is, however, considered to be laborious and unreliable. METHODS: We developed a method to determine the copy number of the CYP2D6*5 and CYP2D6*2xN alleles by use of Pyrosequencing technology. A single set of PCR and sequencing primers was used to coamplify and sequence a region in the CYP2D6 gene and the equivalent region in the CYP2D8P pseudogene, and relative quantification between these fragments was performed. The CYP2D8P-specific Pyrosequencing peak heights were used as references for the CYP2D6-specific peak heights. RESULTS: Analysis of 200 pregenotyped samples showed that this approach reliably resolved 0-4 genome copies of the CYP2D6 gene. In 15 of these samples, the peak pattern from one analyzed position was unexpected but could be solved by conclusive results from a second position. The method was verified on 270 other samples, of which 267 gave results that corresponded to the expected genotype. One of the samples could not be interpreted. The reproducibility of the method was high. CONCLUSIONS: CYP2D6 gene copy determination by Pyrosequencing is a reliable and rapid alternative to other methods. The use of an internal CYP2D8P control as well as generation of a sequence context ensures a robust method and hence facilitates method validation.


Assuntos
Citocromo P-450 CYP2D6/genética , Sequência de Bases , Dosagem de Genes , Humanos , Dados de Sequência Molecular , Reação em Cadeia da Polimerase/métodos , Reprodutibilidade dos Testes , Alinhamento de Sequência
9.
J Anal Toxicol ; 28(2): 94-104, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15068562

RESUMO

Citalopram, a selective serotonin reuptake inhibitor, is one of the most commonly found drugs in Swedish forensic autopsy cases. Citalopram is a racemic drug with 50:50 of the S- and R- enantiomers. Enantioselective analysis of citalopram and its metabolites desmethylcitalopram and didesmethylcitalopram were performed in femoral blood from 53 autopsy cases by a chiral high-performance liquid chromatography (HPLC) method. The mean (+/- standard deviation) S/R ratio for citalopram was 0.67 +/- 0.25 and for desmethylcitalopram, 0.68 +/- 0.20. We found increasing S/R ratios with increasing concentrations of citalopram. We also found that high citalopram S/R ratios were associated with a high parent drug-to-metabolite ratio and may be an indicator of recent intake. Citalopram is metabolized by cytochrome P450 (CYP) 3A4, 2C19, and 2D6. Genotyping for the polymorphic CYP2C19 and CYP2D6 revealed no poor metabolizers regarding CYP2C19 and only 2 (3.8%) poor metabolizers regarding CYP2D6. The presence of drugs metabolized by and/or inhibiting these enzymes in several of the cases suggests that such pharmacokinetic interactions are a more important (practical) problem than metabolic deficiency. Enantioselective analysis of citalopram and its metabolites can provide additional information when interpreting forensic toxicology results and might be a necessity in the future.


Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , Citalopram/sangue , Citocromo P-450 CYP2D6/genética , Oxigenases de Função Mista/genética , Inibidores Seletivos de Recaptação de Serotonina/sangue , Detecção do Abuso de Substâncias/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Hidrocarboneto de Aril Hidroxilases/sangue , Causas de Morte , Cromatografia Líquida de Alta Pressão , Citalopram/análogos & derivados , Citalopram/farmacocinética , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP2D6/sangue , DNA/análise , Feminino , Medicina Legal/métodos , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Oxigenases de Função Mista/sangue , Inibidores Seletivos de Recaptação de Serotonina/farmacocinética , Estereoisomerismo , Fatores de Tempo
10.
Pharmacol Toxicol ; 93(6): 297-304, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14675464

RESUMO

Increased expression of P-glycoprotein encoded by the mdr-1 gene is a well-characterised mechanism for resistance to cancer chemotherapeutic drugs in cell lines. However, the P-glycoprotein expression after removal of the selection pressure has not fully been elucidated. The stability of P-glycoprotein expression in the presence (+) and absence (-) of vincristine (30 or 150 nM) was studied in multidrug resistant K562 cell lines (VCR30+, VCR150+, VCR30- and VCR150-) for 11 months. The P-glycoprotein protein and mdr-1 mRNA levels were determined at regular intervals using flow cytometry and real-time PCR, respectively. Chemosensitivity to a panel of antineoplastic drugs was measured using an MTT assay. The presence of vincristine (VCR30+ and VCR150+) resulted in high and stable levels of P-glycoprotein and mdr-1 mRNA during the whole period compared to wild type. As for the VCR30- and VCR150- subcultures, the expressions of P-glycoprotein and mdr-1 mRNA were stable for five months, and then the levels decreased rapidly. Concomitantly, the sensitivity to drugs known as P-glycoprotein substrates was restored. In conclusion, resistant cells growing in the presence of the inducing drug have a stable P-glycoprotein expression and resistance level, but removing the inducing drug may result in a sudden and rapid lowering of P-glycoprotein and mdr-1 mRNA levels as long as five months after drug withdrawal.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Antineoplásicos/farmacologia , Linhagem Celular Tumoral/efeitos dos fármacos , Genes MDR/efeitos dos fármacos , Citometria de Fluxo , Humanos , RNA/isolamento & purificação
11.
Eur J Clin Pharmacol ; 59(7): 521-6, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-13680033

RESUMO

OBJECTIVE: To develop a single nucleotide polymorphism (SNP) analysis for identification of cytochrome P450 (CYP)2D6 alleles by pyrosequencing. METHODS: Swedish blood donors ( n=282) were typed for a partial CYP2D6 genotype comprising the alleles *1 (wild type), *2 (2850C>T), *3 (2549A>del), *4 (1846G>A) and *6 (1707T>del) using polymerase chain reaction (PCR) and pyrosequencing analysis. CYP2D6*5 (CYP2D6 deleted) was identified using an established long multiplex PCR method. Pyrosequencing is a sequencing-by-synthesis method in which a cascade of enzymatic reactions yields detectable light, which is proportional to the incorporated nucleotides. One feature of typing SNPs by pyrosequencing is that each allelic variant will give a unique sequence. These variants can be readily distinguished by pattern recognition software. RESULTS: Of 281 individuals analysed, 24 (8.5%) were found to be poor metabolisers with two non-functional alleles. This is in the range of 7-10%, previously reported for Caucasians. A total of 126 individuals (45%) had one functional and one non-functional allele and 131 individuals (47%) had two functional alleles. CONCLUSION: Pyrosequencing was found to be a fast and efficient tool for genotyping. The method is robust, reliable, rapid and has high throughput.


Assuntos
Citocromo P-450 CYP2D6/genética , Polimorfismo de Nucleotídeo Único/genética , Análise de Sequência de DNA/métodos , População Branca/genética , Alelos , Primers do DNA , Humanos , Reação em Cadeia da Polimerase , Suécia
12.
Eur J Clin Pharmacol ; 58(2): 103-8, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12012141

RESUMO

OBJECTIVE: This aim of this study was to compare the pharmacokinetics of topotecan in the presence and absence of preceding amifostine to reduce the risk of side effects in patients with advanced ovarian cancer. METHODS: Ten patients with advanced ovarian cancer received topotecan, 1.5 mg/m(2) for 5 days, as second-line therapy in an open phase-II study after previous platinum-containing first-line therapy. Patients were randomised to receive intravenous (IV) amifostine at a daily dose of 300 mg/m(2) prior to topotecan in the first cycle and topotecan alone in the second cycle or vice versa. Thereafter all patients were given amifostine and topotecan for additional four cycles. Topotecan was given as a 30-min IV infusion. On day 1 of the first and second treatment cycles, venous blood samples were collected up to 24 h after the start of topotecan infusion. Plasma concentrations of total topotecan and its active lactone form were determined using high-performance liquid chromatography. RESULTS: There was a rapid decline in total topotecan plasma concentrations after the end of the infusion followed by a slower decay. The initial decline was even faster for the lactone form. The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine. The geometric mean of AUC(0-infinity) values were 326 nmol/l h and 297 nmol/l h, respectively ( P=0.41). In the cycles when the patients received topotecan alone, the plasma AUC of the lactone averaged 40% of the AUC of the total concentration compared with 39% in the cycles when topotecan was given after amifostine. The peak plasma concentration (C(max)) of the lactone averaged 72% of the C(max) of the total topotecan concentration in the topotecan-only group. The corresponding figure after topotecan and amifostine was 80% ( P=0.11). A large intra-individual pharmacokinetic of topotecan between cycles 1 and 2 was also observed. CONCLUSION: Amifostine, 300 mg/m(2), does not significantly affect the pharmacokinetics of topotecan and there are pronounced intra- and inter-individual variabilities in the topotecan pharmacokinetics.


Assuntos
Amifostina/farmacologia , Antineoplásicos/farmacocinética , Neoplasias Ovarianas/tratamento farmacológico , Topotecan/farmacocinética , Adulto , Idoso , Antineoplásicos/sangue , Antineoplásicos/uso terapêutico , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Interações Medicamentosas , Feminino , Humanos , Infusões Intravenosas , Pessoa de Meia-Idade , Neoplasias Ovarianas/metabolismo , Topotecan/sangue , Topotecan/uso terapêutico
13.
Cancer Lett ; 178(2): 141-9, 2002 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-11867198

RESUMO

Anthracycline antibiotics are widely used as anticancer agents. Idarubicin (4-demethoxydaunorubicin; Ida), a semisynthetic derivative of daunorubicin (Dnr) is more potent than the parent compound in vitro and in vivo. The equitoxic dose of Ida in patients is about one-fourth of that of Dnr. We compared these drugs regarding cytotoxicity, apoptosis induction, and resistance mechanisms in human leukaemic cell lines. Cytotoxicity was studied by means of the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay and drug-induced apoptosis by means of the Annexin V-fluorescein isothiocyanate method at similar intracellular concentrations (extracellular concentrations of 0.35 microM for Ida and 1 microM for Dnr). Ida was at least twice as potent as Dnr in MOLT-4, HL60, CEM, and K562 cell lines. It took 8 h for Ida to induce approximately 20% apoptosis, but at least 22 h for Dnr to reach 20% apoptosis at identical intracellular concentration. Ida induces a faster and higher apoptosis rate compared with Dnr. The human chronic myelogenous leukaemia cell line (K562) was selected for resistance to Dnr and Ida with and without verapamil (Ver). Continuous incubation with Dnr, but not with Ida, led to an increased mdr1 gene expression as assessed by real-time PCR. The development of mdr1 gene expression in Dnr-resistant cells could be reversed by the presence of Ver. Ver also reversed the cytotoxicity to Dnr, but not to Ida, in K562/Dnr cells. The results show that Ida is more effective than Dnr in inducing apoptosis and that there are differences in resistance mechanisms between the drugs.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Daunorrubicina/farmacologia , Idarubicina/farmacologia , Leucemia , Antibióticos Antineoplásicos/uso terapêutico , Sobrevivência Celular/efeitos dos fármacos , Daunorrubicina/uso terapêutico , Resistência a Medicamentos , Resistencia a Medicamentos Antineoplásicos , Humanos , Idarubicina/uso terapêutico , Leucemia/tratamento farmacológico , Leucemia/patologia , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...